Quanyin Hu, assistant professor of pharmacy, and postdoctoral researcher Peixin Liu have developed McR-TACs, a new class of protein degrader that targets disease-related proteins on and outside cells. These degraders are recycled by cells after breaking down target proteins, meaning fewer doses may be needed to maintain treatment effects. Tested in cancer cell models, this approach could improve immunotherapy treatments by making them more durable and effective.
Ready for a closer look? This quick animated video shows the technology in motion.